China Securities Intelligence Finance Weili Medical(603309) announced on the evening of May 22 that the company recently received a Class 2 medical device certificate issued by the Canadian Ministry of HealthProduct registration certificate, the company's product extraction bag (Extraction Bag) has been certified by the Canadian Ministry of Health.

　　This product has two registration certificates because of the differences in design structure and working principle of different models. Product name: Extraction Bag. The certificate numbers are 113343 and 113348 respectively; the models/specifications are Type A (200ml, 400ml, 800ml), Type B (300ml, 550ml, 800ml), and Type C (300ml, 550ml, 800ml). The certification date is May 20, 2025.

　　The announcement stated that the certification obtained from the Canadian Ministry of Health indicates that it can be legally sold in the Canadian market, which will play a positive role in promoting and selling the product in overseas markets.

　　According to the data, Weili Medical is mainly engaged in the research, production and sales of medical devices in the fields of anesthesia, catheterization, urology, nursing, respiration, hemodialysis, etc. Its products have effectively covered all provinces and regions in the country and entered more than 5,000 hospitals, including more than 1,000 tertiary hospitals, and established a professional academic promotion team. The company has obtained more than 500 medical device registration certificates of various types worldwide, and has business cooperation with hundreds of foreign medical device distributors and dozens of domestic export traders. Its products are exported to hundreds of countries and regions overseas and have entered the mainstream markets with strict supervision such as North America, Europe, and Japan.

　　In 2024, the company achieved total operating revenue of 1.509 billion yuan, a year-on-year increase of 8.76%; net profit attributable to the parent company was 219 million yuan, a year-on-year increase of 13.98%. In the first quarter of 2025, the company achieved total operating revenue of 348 million yuan, a year-on-year increase of 12.60%; net profit attributable to the parent company was 58.9238 million yuan, a year-on-year increase of 17.25%.

https://finance.eastmoney.com/a/202505223412055511.html